HASAN PHARMA LTD

What HASAN PHARMA LTD does

Hasan-Dermapharm (operating as HASAN PHARMA LTD) is a private for-profit pharmaceutical company founded in 2004 that develops and manufactures generic drugs. According to its firmographic profile, the company's therapeutic portfolio spans cardiovascular, neurological, diabetes, lipid, and other therapy areas, indicating a broad generic-pharma footprint rather than specialization in a single disease category.

The company's primary business activity is the development and manufacturing of off-patent small-molecule generics across multiple chronic-disease therapeutic areas. The company operates through a for-profit, private structure (no public ticker) and maintains a web presence at hasanderma.com, though the live webpage returned only a Cloudflare-style loading/verification interstitial at the time of data collection and provided no additional substantive content on products, pipeline, manufacturing sites, or certifications.

Business model mechanics, pricing, distribution channels, customer segments, headcount, revenue, funding history, management team, and operating geographies are not disclosed in the available source material. No products and services catalog, no certifications or compliance records (e.g., GMP, FDA, EMA), no patents or trademarks, and no partnerships or distribution agreements are available. As a result, the company's go-to-market model — whether domestic-focused, export-oriented, tender-driven, or B2B API/finished-dose licensing — cannot be determined from the input. The data gap around corporate, financial, and operational specifics is material and limits any deeper assessment of competitive position or scale.

Name

HASAN PHARMA LTD

Website

https://hasanderma.com

Company type

Private

Founded year

2004

Short description

Hasan-Dermapharm (HASAN PHARMA LTD) is a private generic pharmaceutical manufacturer founded in 2004, developing and producing therapies in cardiovascular, neurological, diabetes, lipid, and other disease areas.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Generic pharmaceuticals
• Drug manufacturing
• Cardiovascular medications
• Diabetes therapies
• Lipid management drugs

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Core offering

Hasan-Dermapharm develops and manufactures generic pharmaceuticals for cardiovascular, neurological, diabetes, lipid, and other therapies. The company produces off-patent drug formulations for use across multiple therapeutic areas, operating as a privately held drug manufacturer founded in 2004.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic cardiovascular pharmaceuticals Generic drug formulations for cardiovascular therapy, manufactured and sold by Hasan-Dermapharm for use by pharmaceutical distributors, pharmacies, hospitals, and healthcare procurement organizations.
• Generic neurological pharmaceuticals Generic drug formulations for neurological therapy, manufactured and sold by Hasan-Dermapharm for use by pharmaceutical distributors, pharmacies, hospitals, and healthcare procurement organizations.
• Generic diabetes pharmaceuticals Generic drug formulations for diabetes therapy, manufactured and sold by Hasan-Dermapharm for use by pharmaceutical distributors, pharmacies, hospitals, and healthcare procurement organizations.
• Generic lipid-management pharmaceuticals Generic drug formulations for lipid management therapy, manufactured and sold by Hasan-Dermapharm for use by pharmaceutical distributors, pharmacies, hospitals, and healthcare procurement organizations.
• Other generic therapy pharmaceuticals Generic drug formulations for additional therapy areas beyond cardiovascular, neurological, diabetes, and lipid conditions, manufactured and sold by Hasan-Dermapharm for use by pharmaceutical distributors, pharmacies, hospitals, and healthcare procurement organizations.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Cipla: Indian generic pharma company with strong chronic-disease portfolios in respiratory, cardiovascular, and CNS — comparable as a manufacturer of high-volume, off-patent small-molecule generics.
• Aurobindo Pharma: India-based manufacturer of generic small-molecule pharmaceuticals across cardiovascular, CNS, diabetes, and lipid categories — closely overlapping Hasan-Dermapharm's therapeutic portfolio and small-molecule generic manufacturing model.
• Sun Pharmaceutical Industries: Large Indian generic manufacturer with deep presence in chronic-disease categories including cardiology, neurology, and diabetes — comparable therapeutic breadth and finished-dosage-form manufacturing approach.
• Lupin Limited: Indian generic manufacturer with significant cardiovascular, diabetes, and CNS franchises — comparable portfolio composition and small-molecule generic manufacturing approach.
• Dr. Reddy's Laboratories: India-headquartered generics manufacturer with active franchises in cardiovascular, diabetes, and CNS — comparable therapeutic focus and finished-dosage generic manufacturing model.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad small-molecule generic portfolios including cardiovascular, CNS, and metabolic categories — comparable breadth but vastly larger scale and global footprint.
• Viatris (formerly Mylan): Global generics powerhouse with established franchises across cardiovascular, diabetes, and CNS — comparable product categories but operates at global scale with significantly broader portfolio.
• Sandoz (Novartis generics): Global leader in small-molecule generics with significant presence in cardiovascular and CNS — comparable manufacturing model and therapeutic categories, but materially larger scale.

Regional players

• Beximco Pharmaceuticals: Bangladesh-based generic pharmaceutical manufacturer with broad therapeutic coverage including cardiovascular, CNS, and diabetes — directly comparable in therapeutic scope and South Asian emerging-market context.
• Square Pharmaceuticals: Bangladesh's largest pharmaceutical company, manufacturing generics across cardiovascular, CNS, diabetes, and lipid categories — directly comparable in therapeutic portfolio and regional manufacturing footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HASAN PHARMA LTD